Peptide therapy gets talked about as if it were a single decision: yes or no, in or out. It is not. "Peptides" is a broad category of compounds studied for very different purposes, at very different stages of evidence, under very different legal statuses. Some, like semaglutide and tirzepatide, are FDA-approved drugs with large human trials behind them. Others are investigational, studied mostly in animals, and not approved for the uses people buy them for. Deciding whether any of this is right for you starts with being honest about which bucket a given compound falls into and what the research actually shows.
The Peptide Foundation does not sell peptides, prescribe them, or take money from the providers it rates. This guide is meant to help you think through candidacy honestly, including the many situations where the honest answer is "not this, not now, or not without more evidence."
First, Separate the Regulated From the Unregulated
Before you weigh any personal factor, understand the legal landscape, because it determines whether a product is even something a physician can responsibly dispense. A licensed 503A or 503B compounding pharmacy can prepare certain peptides for a patient with a valid prescription. That is a regulated supply chain with a prescriber and a pharmacist accountable for what is in the vial. Outside that system is a large gray market of "research use only" products sold direct to consumers, with no prescription, no pharmacy oversight, and no guarantee of what they actually contain. Reporting has documented the health concerns tied to that unregulated market.
What the Research Actually Shows
This is where honesty matters most. Much of what is marketed around peptides rests on early, preclinical, or narrow evidence, and it is easy to mistake a promising mouse study for a proven human treatment. Here is a grounded read of a few categories people ask about.
Growth-hormone-releasing peptides such as sermorelin, ipamorelin, and CJC-1295 have been studied for their ability to prompt the pituitary to release growth hormone. Early human pharmacology studies suggest they can raise GH and IGF-1 levels, and CJC-1295 with ipamorelin is a common pairing in this class. What that translates to for body composition, energy, or aging in otherwise healthy adults is far less settled, and most of these are used off-label. Tesamorelin is the most rigorously studied of the group, with FDA approval specifically for reducing excess visceral fat in people with HIV-associated lipodystrophy, which is a narrow, approved indication rather than a general anti-aging endorsement.
Repair-focused peptides like BPC-157 and TB-500 are frequently promoted for tendon, muscle, and gut healing. The supportive research is largely in animal models, where early studies have associated BPC-157 with faster soft-tissue and tendon healing and TB-500 (thymosin beta-4) with accelerated wound healing. These effects have not been established in humans through the kind of controlled trials that support an approved drug claim, and BPC-157 remains outside the approved compounding framework.
For sleep, DSIP has small, older human studies that suggest effects on sleep behavior, but the evidence base is thin by modern standards. For sexual health, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women, one of the clearer approvals in this space, and is used off-label beyond that population. For skin, GHK-Cu has laboratory and topical research on collagen and skin repair pathways, though this has not been proven to reverse aging in the way marketing often implies.
The pattern across the category is consistent: interesting mechanisms, some genuinely strong evidence in specific approved uses, and a lot of extrapolation beyond what the studies actually tested. A good candidacy conversation names that gap out loud rather than papering over it.
Signs Peptide Therapy May Be Worth Investigating
None of the following means a peptide will help you. They describe situations where a legitimate, physician-supervised evaluation is a reasonable next step, so a prescriber can decide whether an evidence-supported option applies to you.
- You have documented lab abnormalities, such as low IGF-1, that a physician wants to evaluate rather than a vague sense that you should "optimize."
- You have an approved indication a peptide is actually cleared for, and you want to discuss it with a licensed prescriber.
- You have already addressed the foundations, sleep, nutrition, movement, and stress, and want a clinician to assess whether anything further is warranted.
- You want oversight and lab monitoring, not a vial ordered from an unregulated website.
- You are comfortable with the fact that many of these uses are investigational and unproven in humans, and you want a prescriber who will tell you that plainly.
When Peptide Therapy Is Not Appropriate
Being clear about who should not pursue something is part of honest health information, not a barrier. These are widely recognized cautions, and a responsible prescriber will raise them.
- An active cancer diagnosis or a history of hormone-sensitive cancer. Growth-hormone-stimulating peptides raise theoretical concern about cellular proliferation, and this warrants oncology input.
- Pregnancy or breastfeeding. Safety data for most peptides in this population is insufficient.
- Uncontrolled diabetes or significant insulin resistance, since some GH-stimulating peptides can affect glucose regulation.
- A known hypersensitivity to peptide compounds.
- An expectation of fast, guaranteed results. Any biological effects would act on their own timelines, and for many uses the human evidence simply is not there.
- A desire to skip lab work or medical oversight entirely, which points toward the unregulated market the Foundation excludes.
Questions People Commonly Ask
Are peptides the same as anabolic steroids or synthetic HGH?
No. Growth-hormone secretagogues such as sermorelin and ipamorelin are studied for signaling the pituitary to release the body's own growth hormone, which is mechanistically different from injecting synthetic HGH or using anabolic steroids. Different mechanism does not automatically mean lower risk or proven benefit, and each compound has to be judged on its own evidence and legal status.
Does insurance cover this?
Usually not. Compounded peptides prescribed off-label are typically not covered. Approved drugs like semaglutide or tirzepatide may be covered for approved indications, which is another reason the regulated-versus-unregulated distinction matters.
Is it safe to just buy peptides online?
Products sold as "research use only" outside the licensed pharmacy system carry no guarantee of identity, purity, or dose, and reporting has tied that gray market to real health concerns. That is precisely the category the Foundation excludes from its ratings.
How to Find Safe, Legal Care
If you decide the conversation is worth having, have it with a licensed clinician working through the legitimate pharmacy system, not a website selling vials. The Foundation maintains a provider directory of clinics evaluated on the criteria described in how we rate, including whether they dispense through licensed 503A/503B pharmacies with a prescription, how they handle labs and monitoring, and how honestly they represent the evidence. You can also review our FAQ for common questions. Use the directory to find a prescriber who will give you a candid assessment, including telling you when the honest answer is no.
The Bottom Line
"Is peptide therapy right for you?" is really several questions: Is this specific compound legal and available through a regulated pharmacy? What does the actual human evidence show for the use you have in mind? Do you have a condition or lab finding a physician can genuinely act on? And are you working with a prescriber who will be straight with you? If the answers point toward a supervised, evidence-honest path, that is a reasonable route to explore. If they point toward buying unregulated products chasing unproven promises, the honest answer is to step back. Either way, start with the evidence, not the marketing.